Korean J Hepatol.
1997 Mar;3(1):29-39.
Changes of Epidermal Growth Factor in Sera among the Patients with Chronic Hepatitis, Cirrhosis and Hepatocellular Carcinoma
Abstract
- BACKGROUND/AIMS
Epidermal growth factors (EGF) is known to activate mitogen
activated protein kinase (MAP kinase) in hepatocytes by the route of both Raf-dependent
and Raf-indefendent pathways. And this is likely to play important role in normal liver
cell growth and regeneration. EGF is also reported as a potent mitogen and one of the
angiogenic factors. To elucidate the dynamic changes of the serum concentration of
epidermal growth factor in chronic liver disease and its correlation with role of EGF
and mechanism of tumor development, this study is intended to employ an ELISA in 38
biopsy-proven cases.
METHODS
Sera taken out of 5 patients with chronic persistent hepatitis. 4 patients
with chronic active hepatitis, 19 patients with liver cirrhosis, 10 patients with
hepato-cellular carcinoma that pathological diagnosis was proven later were tested for
EGF employing Quantikine ELISA Kits (R & D Systems Inc. Minneapolis, MN).
The statistical analysis was evaluated by student's t-test.
RESULTS
EGF concentration was 253.33+ 69.5pg/ml(Mean+ SE) in hepatocellular carcinoma,
246.60+ 91.19pg/ml(Mean+ SE) in chronic active hepatitis, 222.71+ 115.97pg/ml (Mean+ SE)
in chronic persistent hepatitis, 141.15+ 23.12pg/ml(Mean+ SE) in liver cirrhosis in orders.
Serum EGF concentration in hepatocellular carcinoma was significantly higher than
that in liver cirrhosis(p value=0.021695). However, comparing to the remaining
other groups, no significant difference was found.
CONCLUSION
These results support that the reconstruction of the capillary networks
in liver cirrhosis resplts in down-regulation of the EGF in comparison to chronic hepatitis.
But it is suggested that revaluation of EGF stimulates MAP kinase activity eventually
playing in tumorigenesis of the liver with neoangiogenesis.